These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 4943872

  • 1. The therapeutic possibilities of L-dopa and amantadine in Parkinsonian patients who have undergone bilateral thalamotomy.
    Giuffrè R, Gambacorta D.
    Eur Neurol; 1971; 5(5):311-6. PubMed ID: 4943872
    [No Abstract] [Full Text] [Related]

  • 2. Clinical evaluation of amantadine therapy for parkinsonism and the side effects--in cases of thalamic surgery and L-dopa therapy.
    Matsumoto K, Omoto T, Beck H.
    Folia Psychiatr Neurol Jpn; 1974 Jan; 28(1):1-10. PubMed ID: 4406943
    [No Abstract] [Full Text] [Related]

  • 3. Amantadine for Parkinson's disease.
    Mann DC, Pearce LA, Waterbury LD.
    Neurology; 1971 Sep; 21(9):958-62. PubMed ID: 4936828
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of the Parkinson syndrome with amantadine].
    Hartmann-von Monakow K.
    Schweiz Med Wochenschr; 1971 Dec 04; 101(48):1736-9. PubMed ID: 5140093
    [No Abstract] [Full Text] [Related]

  • 5. The influence of a previous thalamotomy on the L-dopa effects on mono-manual dexterity in parkinsonism.
    Knutsson E, Mårtensson A, Meyerson BA, Risberg AM.
    Scand J Rehabil Med; 1973 Dec 04; 5(3):130-3. PubMed ID: 4754551
    [No Abstract] [Full Text] [Related]

  • 6. [Effects of 1-adamantil-amine chlorhydrate on parkinsonian asynkinesia].
    Megna G.
    Acta Neurol (Napoli); 1971 Dec 04; 26(6):701-6. PubMed ID: 4946490
    [No Abstract] [Full Text] [Related]

  • 7. Interactions of L-dopa and amantadine in patients with Parkinsonism.
    Cox B, Danta G, Schnieden H, Yuill GM.
    J Neurol Neurosurg Psychiatry; 1973 Jun 04; 36(3):354-61. PubMed ID: 4714097
    [Abstract] [Full Text] [Related]

  • 8. Stereotaxic intracerebral instillation of dopa.
    Velasco Suárez MM, Escobedo FR.
    Confin Neurol; 1970 Jun 04; 32(2):149-57. PubMed ID: 4926179
    [No Abstract] [Full Text] [Related]

  • 9. [Psychologic evaluation of amantadine treatment of parkinsonism and comparative analysis of the effects with L-dopa].
    Puca FM, Micalizzi V, Megna GF, Barbieri NF, Pigneri MT.
    Acta Neurol (Napoli); 1971 Jun 04; 26(6):707-30. PubMed ID: 4946491
    [No Abstract] [Full Text] [Related]

  • 10. [Clinical and electromyographic controls of the effect of dopamine in parkinsonian patients].
    Tzavellas O, Umbach W.
    Arch Psychiatr Nervenkr (1970); 1967 Jun 04; 209(3):227-40. PubMed ID: 5340022
    [No Abstract] [Full Text] [Related]

  • 11. [Iron, transferrin, copper and ceruloplasmin of the serum and cerebrospinal fluid in extrapyramidal diseases and primary myopathies. Study in basic conditions and in Parkinsonism after treatment with dopaminergic agents (L-dopa, L-dopa + RO 4-4602, amantadine)].
    Campanella G, Carrieri P, Romito D, Pasqual-Marsettin E.
    Acta Neurol (Napoli); 1973 Jun 04; 28(1):1-34. PubMed ID: 4704396
    [No Abstract] [Full Text] [Related]

  • 12. L-dopa in the treatment of Parkinsonism; a preliminary appraisal.
    Stellar S, Mandell S, Waltz JM, Cooper IS.
    J Neurosurg; 1970 Mar 04; 32(3):275-80. PubMed ID: 5416909
    [No Abstract] [Full Text] [Related]

  • 13. [Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa].
    Ambrosetto C, Martinelli P.
    Minerva Med; 1971 Oct 31; 62(82):4017-9. PubMed ID: 5125069
    [No Abstract] [Full Text] [Related]

  • 14. The management of Parkinson's syndrome.
    Wanger SL.
    Med Clin North Am; 1972 May 31; 56(3):693-709. PubMed ID: 4556201
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of amantadine, placebo, and levodopa in Parkinson's disease.
    Bauer RB, McHenry JT.
    Neurology; 1974 Aug 31; 24(8):715-20. PubMed ID: 4858417
    [No Abstract] [Full Text] [Related]

  • 16. L-dopa for parkinsonism.
    Reveno WS, Bauer RB, Rosenbaum H.
    Geriatrics; 1973 Jan 31; 28(1):86-8. PubMed ID: 4683093
    [No Abstract] [Full Text] [Related]

  • 17. Amantadine versus L-2 dopa and amatadine plus L-dopa.
    Fieschi C, Nardini M, Casacchia M, Tedone ME, Reitano M, Robotti E.
    Lancet; 1970 Jul 18; 2(7664):154-5. PubMed ID: 4194541
    [No Abstract] [Full Text] [Related]

  • 18. [The addition of amantadine to prolonged treatment with L-Dopa. Considerations on 20 cases].
    Giuffrè R, Gambacorta D.
    Minerva Med; 1971 Oct 31; 62(82):4009-12. PubMed ID: 5125066
    [No Abstract] [Full Text] [Related]

  • 19. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
    Danielczyk W, Korten JJ.
    Med Monatsschr; 1971 Oct 31; 25(10):472-9. PubMed ID: 5122447
    [No Abstract] [Full Text] [Related]

  • 20. Combined L-dopa and amantadine in Parkinsonism.
    Pollock M, Jorgensen PB.
    Aust N Z J Med; 1972 Aug 31; 2(3):252-5. PubMed ID: 4564049
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.